

Regen Bio's dCellVax IND on go

Nov. 4, 2014 12:47 PM ET | About: Regen Biopharma, Inc. (RGBP) | By: Douglas W. House, SA
News Editor

- The FDA issues IND No. 16200 to Regen BioPharma (OTCPK:RGBP -1.9%) for a proposed Phase 1/2 clinical trial to evaluate dCellVax for the treatment for breast cancer. The one-year study will recruit 10 patients with metastatic breast cancer. Each will receive four monthly injections of the dCellVax gene silenced dendritic cell therapy. Patients will be assessed at six and twelve months.